Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests

INTRODUCTION: Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashhadi, Mohammad Ali, Kaykhaei, Mahmoud Ali, Mohammadi, Mahdi, Hashemi, Mahdi, Mohamadi Fatide, Tahere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305377/
https://www.ncbi.nlm.nih.gov/pubmed/25642304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305377/
https://www.ncbi.nlm.nih.gov/pubmed/25642304

Ejemplares similares